Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system.

This week, a number of companies, big and small, shared updates on their cardiovascular technology innovations at EuroPCR 2025 in Paris.

MILPITAS, Calif., March 18, 2025--(BUSINESS WIRE)--Elixir Medical is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. This year’s ...

MILPITAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced EU MDR CE Mark approval and commercial ...

BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX ® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies ...

Elixir Medical has joined the growing intravascular lithotripsy (IVL) market following the CE marking of its LithiX Hertz Contact system. The LithiX device employs focal stress contact points to ...

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...

Clinical follow-up will continue through five years. BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX® bioadaptor clinical evidence program consisting of nine company ...

MILPITAS, Calif., March 18, 2025--(BUSINESS WIRE)--Elixir Medical is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. This year’s list ...